Antithrombotic therapy after TAVI: Better alone than with a bad company.

Abstract

Key Points In transcatheter aortic valve implantation (TAVI) subset, previous randomized controlled trials reported increased mortality when anticoagulant therapy was used in subjects without a previous oral anticoagulation (OAC) indication. The current meta‐analysis confirms the worse clinical outcomes in anticoagulated patients as compared to subjects treated with antiplatelet, tough less subclinical valve thrombosis was found in the OAC group. At present, antiplatelet therapy (especially SAPT) seems the most reasonable approach in TAVI patients without indications for chronic OAC.